Poseida Therapeutics, Inc. Net Change in Cash
Poseida Therapeutics, Inc. reported Net Change in Cash of $4.87 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2024-11-07
- Poseida Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $8.82M.
- Poseida Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$41.23M.
- Poseida Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-03-31 was -$22.84M, a 126.61% decline year-over-year.
- Poseida Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2021-03-31 was $85.83M.
- Poseida Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$36.91M.
- Poseida Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$124.95M, a 202.12% decline from fiscal 2021.
- Poseida Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was $122.36M.
- Poseida Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was -$3.82M, a 106.65% decline from fiscal 2019.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2024-09-30 | $4.87M 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | -$13.93M 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | $8.82M 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | -$36.91M 10-K · filed 2024-03-07 | |||
| 2023-09-30 | -$55.88M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$31.47M 10-Q · filed 2024-08-05 | |||
| 2023-03-31 | -$41.23M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$124.95M 10-K · filed 2024-03-07 | |||
| 2022-09-30 | -$41.52M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$143.36M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | -$22.84M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $122.36M 10-K · filed 2023-03-09 | |||
| 2021-09-30 | $113.84M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $115.73M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $85.83M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$3.82M 10-K · filed 2022-03-10 | |||
| 2020-09-30 | -$21.51M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $59.35M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$24.51M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $57.39M 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $63.64M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $107.11M 10-Q · filed 2020-08-20 |